|
1
|
Terrone C, Guercio S, De Luca S, Poggio M,
Castelli E, Scoffone CM, Tarabuzzi R, Scarpa RM, Fontana D and
Rossetti SR: Number of nodes examined and staging accuracy in renal
cell carcinoma (RCC). BJU Int. 91:37–40. 2003. View Article : Google Scholar
|
|
2
|
Motzer RJ, Russo P, Nanus DM and Berg WJ:
Renal-cell carcinoma. Curr Probl Cancer. 21:185–232. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oosterwijk E, Stillebroer AB and Mulders
PFA: Carbonic Anhydrase IX: Its Role as a Biomarker, Diagnostic,
and Therapeutic Target in Renal Cell Carcinoma. Renal Cell
Carcinoma. Figlin R, Rathmell W and Rini B: Springer; Boston, MA:
2012, View Article : Google Scholar
|
|
4
|
Rini BI, Rathmell WK and Godley P: Renal
cell carcinoma. Curr Opin Oncol. 20:300–306. 2008. View Article : Google Scholar
|
|
5
|
Trump DL: 1. Sorafenib in advanced
clear-cell renal-cell carcinoma. Escudier B, Eisen T, Stadler WM,
Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E,
Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S,
Schwartz B, Shan M, Simantov R and Bukowski RM; TARGET Study Group,
: Department of Medicine, Institut Gustave Roussy; Villejuif,
France: Urol Oncol Semin Orig Investig. 25. pp. 443–445. 2007
|
|
6
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N
Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Snauwaert S, Vanhee S, Goetgeluk G,
Verstichel G, Van Caeneghem Y, Velghe I, Philippé J, Berneman ZN,
Plum J, Taghon T, et al: RHAMM/HMMR (CD168) is not an ideal target
antigen for immunotherapy of acute myeloid leukemia. Haematologica.
97:1539–1547. 2012. View Article : Google Scholar
|
|
9
|
Sohr S and Engeland K: RHAMM is
differentially expressed in the cell cycle and downregulated by the
tumor suppressor p53. Cell Cycle. 7:3448–3460. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tilghman J, Wu H, Sang Y, Shi X,
Guerrero-Cazares H, Quinones-Hinojosa A, Eberhart CG, Laterra J and
Ying M: HMMR maintains the stemness and tumorigenicity of
glioblastoma stem-like cells. Cancer Res. 74:3168–3179. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Esguerra KV, Tolg C, Akentieva N, Price M,
Cho CF, Lewis JD, McCarthy JB, Turley EA and Luyt LG:
Identification, design and synthesis of tubulin-derived peptides as
novel hyaluronan mimetic ligands for the receptor for
hyaluronan-mediated motility (RHAMM/HMMR). Integr Biol (Camb).
7:1547–1560. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang C, Li C, Zhang P, Wu W and Jiang X:
Redox responsive hyaluronic acid nanogels for treating RHAMM
(CD168) over-expressive cancer, both primary and metastatic tumors.
Theranostics. 7:1719–1734. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ahmad S, Kolli S, Li DQ, de Paiva CS,
Pryzborski S, Dimmick I, Armstrong L, Figueiredo FC and Lako M: A
putative role for RHAMM/HMMR as a negative marker of stem
cell-containing population of human limbal epithelial cells. Stem
Cells. 26:1609–1619. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hamilton SR, Fard SF, Paiwand FF, Tolg C,
Veiseh M, Wang C, McCarthy JB, Bissell MJ, Koropatnick J and Turley
EA: The hyaluronan receptors CD44 AND Rhamm (CD168) form complexes
with ERK1,2, that sustain high basal motility in breast cancer
cells. J Biol Chem. 282:16667–16680. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jöhrens K, Anagnostopoulos I, Dommerich S,
Raguse JD, Szczepek AJ, Klauschen F and Stölzel K: Expression
patterns of CD168 correlate with the stage and grade of squamous
cell carcinoma of head and neck. Mol Clin Oncol. 6:597–602. 2017.
View Article : Google Scholar
|
|
16
|
Lin SL, Chang D, Chiang A and Ying SY:
Androgen receptor regulates CD168 expression and signaling in
prostate cancer. Carcinogenesis. 29:282–290. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen H, Connell M, Mei L, Gsd R and
Maxwell CA: The nonmotor adaptor HMMR dampens Eg5-mediated forces
to preserve the kinetics and integrity of chromosome segregation.
Mol Biol Cell. 29:786–796. 2018. View Article : Google Scholar
|
|
18
|
Greiner J, Ringhoffer M, Li L, Barth T,
Wölfel T, Döhner H and Schmitt M: The receptor for hyaluronic acid
mediated motility (RHAMM/CD168) is a leukemia associated antigen
eliciting both humoral and cellular immune responses in patients
with acute myeloid leukemia (AML). Cancer Cell Int. 4 (Suppl
1):S552004. View Article : Google Scholar
|
|
19
|
Ishigami S, Ueno S, Nishizono Y, Matsumoto
M, Kurahara H, Arigami T, Uchikado Y, Setoyama T, Arima H, Yoshiaki
K, et al: Prognostic impact of CD168 expression in gastric cancer.
BMC Cancer. 11:1062011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Missinato MA, Tobita K, Romano N, Carroll
JA and Tsang M: Extracellular component hyaluronic acid and its
receptor Hmmr are required for epicardial EMT during heart
regeneration. Cardiovasc Res. 107:487–498. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Heikinheimo K, Kurppa KJ, Laiho A,
Peltonen S, Berdal A, Bouattour A, Ruhin B, Catón J, Thesleff I,
Leivo I and Morgan PR: Early dental epithelial transcription
factors distinguish ameloblastoma from keratocystic odontogenic
tumor. J Dent Res. 94:101–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bidadi B, Liu D, Kalari KR, Rubner M, Hein
A, Beckmann MW, Rack B, Janni W, Fasching PA, Weinshilboum RM and
Wang L: Pathway-based analysis of genome-wide association data
identified SNPs in HMMR as biomarker for chemotherapy-induced
neutropenia in breast cancer patients. Front Pharmacol. 9:1582018.
View Article : Google Scholar
|
|
24
|
Stevens LE, Zhao M, Liu Z and Nguyen D:
Abstract 2269: A novel molecular subset of metastatic lung
adenocarcinoma is defined by the function of the proteoglycan
receptor HMMR. Cancer Res. 75 (Suppl 15):S22692015. View Article : Google Scholar
|
|
25
|
Tang XH, Osei-Sarfo K, Urvalek AM, Zhang
T, Scognamiglio T and Gudas LJ: Combination of bexarotene and the
retinoid CD1530 reduces murine oral-cavity carcinogenesis induced
by the carcinogen 4-nitroquinoline 1-oxide. Proc Natl Acad Sci USA.
111:8907–8912. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pinaire N, Johnson P, Chari N, Spurgers K,
Meyn R and McDonnell T: Abstract #5312: Novel transcriptional
targets of p53 may inhibit cell migration. Cancer Res. 69
(Suppl):S53122009. View Article : Google Scholar
|
|
27
|
Keane M, Craig T, Alföldi J, Berlin AM,
Johnson J, Seluanov A, Gorbunova V, Di Palma F, Lindblad-Toh K,
Church GM and de Magalhães JP: The naked mole rat genome resource:
Facilitating analyses of cancer and longevity-related adaptations.
Bioinformatics. 30:3558–3560. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chu TLH, Connell M, Zhou LX, He ZC, Won J,
Chen H, Rahavi SMR, Mohan P, Nemirovsky O, Fotovati A, et al: Cell
Cycle-Dependent Tumor Engraftment and Migration Are Enabled by
Aurora-A. Mol Cancer Res. 16:16–31. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Murphy JM, Park H and Lim STS: FAK and
Pyk2 in disease. Front Biol. 11:1–9. 2016. View Article : Google Scholar
|
